Recent Progress in Alzheimer’s Disease Research, Part 3: Diagnosis and Treatment

The field of Alzheimer’s disease (AD) research has grown exponentially over the past few decades, especially since the isolation and identification of amyloid-β from postmortem examination of the brains of AD patients. Recently, the Journal of Alzheimer’s Disease (JAD) put forth approximately 300 research reports which were deemed to be the most influential research reports in the field of AD since 2010. JAD readers were asked to vote on these most influential reports. In this 3-part review, we review the results of the 300 most influential AD research reports to provide JAD readers with a readily accessible, yet comprehensive review of the state of contemporary research. Notably, this multi-part review identifies the “hottest” fields of AD research providing guidance for both senior investigators as well as investigators new to the field on what is the most pressing fields within AD research. Part 1 of this review covers pathogenesis, both on a molecular and macro scale. Part 2 review genetics and epidemiology, and part 3 covers diagnosis and treatment. This part of the review, diagnosis and treatment, reviews the latest diagnostic criteria, biomarkers, imaging, and treatments in AD.

[1]  B. Miller,et al.  CME Practice parameter : Diagnosis of dementia ( an evidence-based review ) Report of the Quality Standards Subcommittee of the American Academy of Neurology , 2001 .

[2]  P. Basser,et al.  Microstructural and physiological features of tissues elucidated by quantitative-diffusion-tensor MRI. 1996. , 1996, Journal of magnetic resonance.

[3]  W. M. van der Flier,et al.  CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. , 2009, JAMA.

[4]  R. Coleman,et al.  Use of florbetapir-PET for imaging beta-amyloid pathology. , 2011, JAMA.

[5]  Jeffrey A. James,et al.  Amyloid imaging in mild cognitive impairment subtypes , 2009, Annals of neurology.

[6]  J. Cummings,et al.  The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment , 2005, Journal of the American Geriatrics Society.

[7]  T. Handy,et al.  Resistance training promotes cognitive and functional brain plasticity in seniors with probable mild cognitive impairment. , 2012, Archives of internal medicine.

[8]  Christopher C Rowe,et al.  Tau imaging: early progress and future directions , 2015, The Lancet Neurology.

[9]  Nick C Fox,et al.  Long-Term Follow-Up of Patients Immunized with AN1792: Reduced Functional Decline in Antibody Responders , 2009, Current Alzheimer research.

[10]  Yong He,et al.  Diffusion Tensor Tractography Reveals Abnormal Topological Organization in Structural Cortical Networks in Alzheimer's Disease , 2010, The Journal of Neuroscience.

[11]  S Ourselin,et al.  β-Amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia , 2010, Neurology.

[12]  Kewei Chen,et al.  Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. , 2011, Archives of neurology.

[13]  Chengjie Xiong,et al.  YKL-40: A Novel Prognostic Fluid Biomarker for Preclinical Alzheimer's Disease , 2010, Biological Psychiatry.

[14]  N. Fitz,et al.  Comment on “ApoE-Directed Therapeutics Rapidly Clear β-Amyloid and Reverse Deficits in AD Mouse Models” , 2013, Science.

[15]  L. Lue,et al.  Inhibition of Amyloid-β (Aβ) Peptide-Binding Alcohol Dehydrogenase-Aβ Interaction Reduces Aβ Accumulation and Improves Mitochondrial Function in a Mouse Model of Alzheimer's Disease , 2011, The Journal of Neuroscience.

[16]  O. Sporns,et al.  Mapping the Structural Core of Human Cerebral Cortex , 2008, PLoS biology.

[17]  Amy L. Shelton,et al.  Reduction of Hippocampal Hyperactivity Improves Cognition in Amnestic Mild Cognitive Impairment , 2012, Neuron.

[18]  Mark Slifstein,et al.  Positron emission tomography: imaging and quantification of neurotransporter availability. , 2002, Methods.

[19]  Sean J. Miller,et al.  Comment on “ApoE-Directed Therapeutics Rapidly Clear β-Amyloid and Reverse Deficits in AD Mouse Models” , 2013, Science.

[20]  P. Davies,et al.  Passive Immunization with Anti-Tau Antibodies in Two Transgenic Models , 2011, The Journal of Biological Chemistry.

[21]  Kazuhiko Yanai,et al.  Tau PET Imaging in Alzheimer’s Disease , 2014, Current Neurology and Neuroscience Reports.

[22]  C. Rowe,et al.  Imaging of amyloid β in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism , 2008, The Lancet Neurology.

[23]  D. Praticò.  Antioxidants for Alzheimer disease. , 2013, JAMA neurology.

[24]  K. Rhodes,et al.  The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease , 2016, Nature.

[25]  Nobuhisa Iwata,et al.  19F and 1H MRI detection of amyloid beta plaques in vivo. , 2005, Nature neuroscience.

[26]  Jürgen Götz,et al.  Scanning ultrasound removes amyloid-β and restores memory in an Alzheimer’s disease mouse model , 2015, Science Translational Medicine.

[27]  Min-Ying Su,et al.  Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808. , 2014, Journal of Alzheimer's disease : JAD.

[28]  G. Lithgow,et al.  Amyloid-binding compounds maintain protein homeostasis during ageing and extend lifespan , 2011, Nature.

[29]  D. Selkoe,et al.  Resolving controversies on the path to Alzheimer's therapeutics , 2011, Nature Medicine.

[30]  C. Glabe,et al.  Monoclonal Antibodies against Aβ42 Fibrils Distinguish Multiple Aggregation State Polymorphisms in Vitro and in Alzheimer Disease Brain* , 2014, The Journal of Biological Chemistry.

[31]  E. Siemers,et al.  Delayed-start analysis: Mild Alzheimer's disease patients in solanezumab trials, 3.5 years , 2015, Alzheimer's & dementia.

[32]  Y. Shitaka,et al.  Differential Effects between γ-Secretase Inhibitors and Modulators on Cognitive Function in Amyloid Precursor Protein-Transgenic and Nontransgenic Mice , 2012, The Journal of Neuroscience.

[33]  T. Montine,et al.  Intranasal Insulin Therapy for Alzheimer Disease and Amnestic Mild Cognitive Impairment A Pilot Clinical Trial , 2011 .

[34]  J O Rinne,et al.  Follow-up of [11C]PIB uptake and brain volume in patients with Alzheimer disease and controls , 2009, Neurology.

[35]  G. Logroscino,et al.  Amyloid-directed monoclonal antibodies for the treatment of Alzheimer’s disease: the point of no return? , 2014, Expert opinion on biological therapy.

[36]  Klaus P. Ebmeier,et al.  A meta-analysis of diffusion tensor imaging in mild cognitive impairment and Alzheimer's disease , 2011, Neurobiology of Aging.

[37]  Martin Knapp,et al.  Donepezil and memantine for moderate-to-severe Alzheimer's disease. , 2012, The New England journal of medicine.

[38]  Karl Herholz,et al.  Clinical amyloid imaging in Alzheimer's disease , 2011, The Lancet Neurology.

[39]  Sachin Dixit,et al.  APOE4 Allele Disrupts Resting State fMRI Connectivity in the Absence of Amyloid Plaques or Decreased CSF Aβ42 , 2010, The Journal of Neuroscience.

[40]  H. Engler,et al.  PET imaging of amyloid deposition in patients with mild cognitive impairment , 2008, Neurobiology of Aging.

[41]  C. Cotman,et al.  Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures. , 2012, Archives of neurology.

[42]  C. Kawas,et al.  Sensitivity and Specificity of the Mini‐Mental State Examination for Identifying Dementia in the Oldest‐Old: The 90+ Study , 2007, Journal of the American Geriatrics Society.

[43]  Nick C Fox,et al.  The Diagnosis of Mild Cognitive Impairment due to Alzheimer’s Disease: Recommendations from the National Institute on Aging-Alzheimer’s Association Workgroups on Diagnostic Guidelines for Alzheimer’s Disease , 2011 .

[44]  Yi Su,et al.  Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease , 2016, Science Translational Medicine.

[45]  J. Trojanowski,et al.  Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. , 2010, Archives of neurology.

[46]  Min-Ying Su,et al.  Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. , 2013, Journal of Alzheimer's disease : JAD.

[47]  A. Fagan,et al.  APOE predicts amyloid‐beta but not tau Alzheimer pathology in cognitively normal aging , 2010, Annals of neurology.

[48]  C. Jack,et al.  Evidence for ordering of Alzheimer disease biomarkers. , 2011, Archives of neurology.

[49]  George W Rebok,et al.  Ten‐Year Effects of the Advanced Cognitive Training for Independent and Vital Elderly Cognitive Training Trial on Cognition and Everyday Functioning in Older Adults , 2014, Journal of the American Geriatrics Society.

[50]  Bruce L. Miller,et al.  Appendix B: Practice parameter: Diagnosis of dementia (an evidence-based review): Report of the quality standards subcommittee of the American academy neurology , 2007 .

[51]  D. Nieman,et al.  Physical activity predicts gray matter volume in late adulthood: The Cardiovascular Health Study , 2011 .

[52]  Christian Hölscher,et al.  The Diabetes Drug Liraglutide Prevents Degenerative Processes in a Mouse Model of Alzheimer's Disease , 2011, The Journal of Neuroscience.

[53]  H. Arai,et al.  18F-THK5351: A Novel PET Radiotracer for Imaging Neurofibrillary Pathology in Alzheimer Disease , 2016, The Journal of Nuclear Medicine.

[54]  L. Schneider,et al.  Lack of evidence for the efficacy of memantine in mild Alzheimer disease. , 2011, Archives of neurology.

[55]  Stephen M. Smith,et al.  DTI measures in crossing-fibre areas: Increased diffusion anisotropy reveals early white matter alteration in MCI and mild Alzheimer's disease , 2011, NeuroImage.

[56]  A. Joshi,et al.  Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages. , 2016, Brain : a journal of neurology.

[57]  J T O'Brien,et al.  EFNS guidelines for the diagnosis and management of Alzheimer’s disease , 2010, European journal of neurology.

[58]  H. Arai,et al.  Comparison study of amyloid PET and voxel-based morphometry analysis in mild cognitive impairment and Alzheimer's disease , 2009, Journal of the Neurological Sciences.

[59]  Nick C Fox,et al.  Conversion of amyloid positive and negative MCI to AD over 3 years , 2009, Neurology.

[60]  Alan J. Thomas,et al.  Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial , 2011, The Lancet.

[61]  Nick C Fox,et al.  Revising the definition of Alzheimer's disease: a new lexicon , 2010, The Lancet Neurology.

[62]  Eric B Larson,et al.  Late-life dementias: does this unyielding global challenge require a broader view? , 2009, JAMA.

[63]  A. Dale,et al.  Combining MR Imaging, Positron-Emission Tomography, and CSF Biomarkers in the Diagnosis and Prognosis of Alzheimer Disease , 2010, American Journal of Neuroradiology.

[64]  Cindee M. Madison,et al.  Neural compensation in older people with brain β-amyloid deposition , 2014, Nature Neuroscience.

[65]  J. Schneider,et al.  National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease , 2012, Alzheimer's & Dementia.

[66]  M. Sano,et al.  Current treatment and recent clinical research in Alzheimer's disease. , 2010, The Mount Sinai journal of medicine, New York.

[67]  K. Garber.  Genentech's Alzheimer's antibody trial to study disease prevention , 2012, Nature Biotechnology.

[68]  Kewei Chen,et al.  Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study , 2012, The Lancet Neurology.

[69]  K. Blennow,et al.  Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment , 2009, Neurobiology of Aging.

[70]  M. Robinson,et al.  Recent Progress in Alzheimer's Disease Research, Part 2: Genetics and Epidemiology. , 2018, Journal of Alzheimer's disease : JAD.

[71]  Jeffrey A. James,et al.  Frequent amyloid deposition without significant cognitive impairment among the elderly. , 2008, Archives of neurology.

[72]  D. Selkoe,et al.  The presence of sodium dodecyl sulphate-stable Abeta dimers is strongly associated with Alzheimer-type dementia. , 2010, Brain : a journal of neurology.

[73]  Albert Hofman,et al.  Plasma clusterin and the risk of Alzheimer disease. , 2011, JAMA.

[74]  P. Basser,et al.  Microstructural and physiological features of tissues elucidated by quantitative-diffusion-tensor MRI. , 1996, Journal of magnetic resonance. Series B.

[75]  Talakad G. Lohith,et al.  Preclinical Characterization of 18F-MK-6240, a Promising PET Tracer for In Vivo Quantification of Human Neurofibrillary Tangles , 2016, The Journal of Nuclear Medicine.

[76]  B. Dickerson,et al.  MRI cortical thickness biomarker predicts AD-like CSF and cognitive decline in normal adults , 2012, Neurology.

[77]  R. Wennberg,et al.  A phase I trial of deep brain stimulation of memory circuits in Alzheimer's disease , 2010, Annals of neurology.

[78]  D. Holtzman,et al.  In Vivo Microdialysis Reveals Age-Dependent Decrease of Brain Interstitial Fluid Tau Levels in P301S Human Tau Transgenic Mice , 2011, The Journal of Neuroscience.

[79]  B. Dubois,et al.  Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization , 2003, Neurology.

[80]  Yong He,et al.  Sex- and brain size-related small-world structural cortical networks in young adults: a DTI tractography study. , 2011, Cerebral cortex.

[81]  G. Schellenberg,et al.  Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial. , 2014, JAMA.

[82]  David S. Park,et al.  Amyloid-β42 signals tau hyperphosphorylation and compromises neuronal viability by disrupting alkylacylglycerophosphocholine metabolism , 2009, Proceedings of the National Academy of Sciences.

[83]  Clifford R. Jack,et al.  Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup , 2011, Alzheimer's & Dementia.

[84]  C. Rowe,et al.  Comparison of 11C-PiB and 18F-florbetaben for Aβ imaging in ageing and Alzheimer’s disease , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[85]  Z. Leonenko,et al.  Atomic force microscopy to study molecular mechanisms of amyloid fibril formation and toxicity in Alzheimer’s disease , 2014, Drug metabolism reviews.

[86]  R. Schwarcz,et al.  Kynurenine 3-Monooxygenase Inhibition in Blood Ameliorates Neurodegeneration , 2011, Cell.

[87]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[88]  Nick C Fox,et al.  Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria , 2014, The Lancet Neurology.

[89]  A. Fagan,et al.  Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between β-Amyloid and Tauopathy. , 2016, JAMA neurology.

[90]  P. Reddy,et al.  Mitochondria-targeted antioxidants protect against amyloid-beta toxicity in Alzheimer's disease neurons. , 2010, Journal of Alzheimer's disease : JAD.

[91]  P. Maher,et al.  Amyloid proteotoxicity initiates an inflammatory response blocked by cannabinoids , 2016, npj Aging and Mechanisms of Disease.

[92]  Peter T Nelson,et al.  Clinicopathologic Correlations in a Large Alzheimer Disease Center Autopsy Cohort: Neuritic Plaques and Neurofibrillary Tangles "Do Count" When Staging Disease Severity , 2007, Journal of neuropathology and experimental neurology.

[93]  K. Scearce-Levie,et al.  A Therapeutic Antibody Targeting BACE1 Inhibits Amyloid-β Production in Vivo , 2011, Science Translational Medicine.

[94]  C. Rowe,et al.  Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease , 2011, Annals of neurology.

[95]  Gina N. LaRossa,et al.  [11C]PIB in a nondemented population , 2006, Neurology.

[96]  Robert A. Dean,et al.  Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients , 2016, Alzheimer's & Dementia.

[97]  Kazuhiko Yanai,et al.  18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease. , 2011, Brain : a journal of neurology.

[98]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[99]  Keith A. Johnson,et al.  Validating novel tau positron emission tomography tracer [F‐18]‐AV‐1451 (T807) on postmortem brain tissue , 2015, Annals of neurology.

[100]  W. Klunk,et al.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.

[101]  James E Audia,et al.  Robust Central Reduction of Amyloid-β in Humans with an Orally Available, Non-Peptidic β-Secretase Inhibitor , 2011, The Journal of Neuroscience.

[102]  E. McAuley,et al.  Exercise training increases size of hippocampus and improves memory , 2011, Proceedings of the National Academy of Sciences.

[103]  Denise C. Park,et al.  Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[104]  Sandra E. Black,et al.  Vascular cognitive impairment , 2018, Nature Reviews Disease Primers.

[105]  Daniel P. Costa,et al.  Accuracy of ARGOS Locations of Pinnipeds at-Sea Estimated Using Fastloc GPS , 2010, PloS one.

[106]  N. Toni,et al.  An Effector-Reduced Anti-β-Amyloid (Aβ) Antibody with Unique Aβ Binding Properties Promotes Neuroprotection and Glial Engulfment of Aβ , 2012, The Journal of Neuroscience.

[107]  E. Salmon,et al.  18F‐flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial , 2010, Annals of neurology.

[108]  Katsuhiro Kobayashi,et al.  Memory enhancement and deep-brain stimulation of the entorhinal area. , 2012, The New England journal of medicine.

[109]  J. Morris.  Early-stage and preclinical Alzheimer disease. , 2005, Alzheimer disease and associated disorders.

[110]  Donald A. Wilson,et al.  ApoE-Directed Therapeutics Rapidly Clear β-Amyloid and Reverse Deficits in AD Mouse Models , 2012, Science.

[111]  Sylvia Richardson,et al.  A dominant gain-of-function mutation in universal tyrosine kinase SRC causes thrombocytopenia, myelofibrosis, bleeding, and bone pathologies , 2016, Science Translational Medicine.

[112]  Ge Li,et al.  Age and apolipoprotein E*4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal cognition. , 2006, Archives of neurology.

[113]  D. Paris,et al.  Role of the cannabinoid system in the transit of beta-amyloid across the blood–brain barrier , 2013, Molecular and Cellular Neuroscience.

[114]  Derick R. Peterson,et al.  Plasma phospholipids identify antecedent memory impairment in older adults , 2014, Nature Medicine.

[115]  Magda Tsolaki,et al.  Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study , 2009, The Lancet Neurology.

[116]  P. Basser,et al.  Toward a quantitative assessment of diffusion anisotropy , 1996, Magnetic resonance in medicine.

[117]  Giovanni B. Frisoni,et al.  The Alzheimer’s Association external quality control program for cerebrospinal fluid biomarkers , 2011, Alzheimer's & Dementia.

[118]  Jayanta Debnath,et al.  Inhibition of mTOR by Rapamycin Abolishes Cognitive Deficits and Reduces Amyloid-β Levels in a Mouse Model of Alzheimer's Disease , 2010, PloS one.

[119]  C. Rowe,et al.  Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study , 2013, The Lancet Neurology.

[120]  Alan C. Evans,et al.  Mapping anatomical connectivity patterns of human cerebral cortex using in vivo diffusion tensor imaging tractography. , 2009, Cerebral cortex.

[121]  Henrik Zetterberg,et al.  Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. , 2012, Archives of general psychiatry.

[122]  I. Fried,et al.  Memory enhancement and deep-brain stimulation of the entorhinal area. , 2012, The New England journal of medicine.

[123]  G. Forloni,et al.  The Continuing Failure of Bexarotene in Alzheimer's Disease Mice. , 2015, Journal of Alzheimer's disease : JAD.

[124]  Nick C Fox,et al.  Clinical and biomarker changes in dominantly inherited Alzheimer's disease. , 2012, The New England journal of medicine.

[125]  C. Jack,et al.  An operational approach to National Institute on Aging–Alzheimer's Association criteria for preclinical Alzheimer disease , 2012, Annals of neurology.

[126]  J. Trojanowski,et al.  Imaging of Tau Pathology in a Tauopathy Mouse Model and in Alzheimer Patients Compared to Normal Controls , 2013, Neuron.

[127]  Yi Su,et al.  The relationship between cerebrospinal fluid markers of Alzheimer pathology and positron emission tomography tau imaging. , 2016, Brain : a journal of neurology.

[128]  E. Siemers,et al.  Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. , 2014, The New England journal of medicine.

[129]  Eric M Reiman,et al.  Florbetapir PET analysis of amyloid-β deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study , 2012, The Lancet Neurology.

[130]  Gina N. LaRossa,et al.  Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans , 2006, Annals of neurology.

[131]  Nick C Fox,et al.  Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. , 2014, The New England journal of medicine.

[132]  K. Blennow,et al.  Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study , 2012, The Lancet Neurology.

[133]  John Seibyl,et al.  Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study , 2011, The Lancet Neurology.